Chemokine Therapeutics achieves critical milestone with the start of a phase Ib/II human clinical trial in cancer

05-May-2006

Chemokine Therapeutics Corp. announced that it has started patient dosing in a phase Ib/II clinical trial using CTCE-9908, the Company's lead anti-cancer product. The start of this trial is an important milestone for the Company as it will be the first investigation of CTCE-9908's safety and ability to reduce the spread of cancer in humans after several doses. A previously completed phase I clinical trial demonstrated CTCE-9908 to be safe and well tolerated by study subjects after a single dose. The new phase Ib/II clinical trial will involve testing the drug in up to 30 patients with late stage cancers to evaluate safety and preliminary efficacy. The trial will study CTCE-9908 in patients with some of the most common cancers such as breast, lung, prostate, and ovarian.

In preclinical studies, CTCE-9908 has been shown to reduce cancer metastases by 50-70% and to have demonstrated early evidence of potential anti-angiogenic properties. CTCE-9908 is designed to block the receptors to which the chemokine SDF-1 binds. SDF-1 (Stromal Cell Derived Factor 1) is believed to activate the receptor CXCR4 which has been implicated in cancer growth and metastasis. These receptors are present on most human tumors cells, including lung, breast, prostate, colon, ovarian, bone, brain, and skin cancer. Leading cancer researchers have demonstrated that a high level of CXCR4 expression in cancer cells is correlated to tumor progression, high metastasis rate and low patient survival rate.

https://www.bionity.com/en/news/54474/chemokine-therapeutics-achieves-critical-milestone-with-the-start-of-a-phase-ib-ii-human-clinical-trial-in-cancer.html